Preservation of residual kidney function in hemodialysis patients: reviving an old concept

Kidney International

Volumn 90, Issue 2, 2016, Pages 262-271

  Mathew, Anna T ^a   Fishbane, Steven ^a   Obi, Yoshitsugu ^b   Kalantar Zadeh, Kamyar ^b,c,d  

^a Northwell Health ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

end stage renal disease; incremental hemodialysis; residual kidney function

Indexed keywords

AMINOGLYCOSIDE; CONTRAST MEDIUM; ELECTROLYTE; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; UREA;

AGE; ANEMIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEALTH STATUS; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; NUTRITION; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DIET; PROTEINURIA; QUALITY OF LIFE; RENAL CLEARANCE; RESIDUAL KIDNEY FUNCTION; REVIEW; SEX DIFFERENCE; URINE VOLUME; ADVERSE EFFECTS; BLOOD PRESSURE MONITORING; DRUG EFFECTS; HEMODIALYSIS; KIDNEY; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROTEIN RESTRICTION; URINE;

AMINOGLYCOSIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BLOOD PRESSURE MONITORING, AMBULATORY; CONTRAST MEDIA; DIET, PROTEIN-RESTRICTED; DIURETICS; ELECTROLYTES; HUMANS; HYPERTENSION; HYPOTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MINERALS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RENAL DIALYSIS; UREA;

EID: 84992509255     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.02.037     Document Type: Review

References (113)

1. 1 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66:suppl 1 (2015), S1–S306.
2. 2 O'Hare, A.M., Wong, S.P., Yu, M.K., et al. Trends in the timing and clinical context of maintenance dialysis initiation. J Am Soc Nephrol 26 (2015), 1975–1981.
3. 3 Moist, L.M., Port, F.K., Orzol, S.M., et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11 (2000), 556–564.
4. 4 Perl, J., Huckvale, K., Chellar, M., et al. Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 4 (2009), 1201–1206.
5. 5 Jansen, M.A., Hart, A.A., Korevaar, J.C., et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62 (2002), 1046–1053.
6. 6 Lang, S.M., Bergner, A., Töpfer, M., Schiffl, H., Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 21 (2001), 52–57.
7. 7 McKane, W., Chandna, S.M., Tattersall, J.E., et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 61 (2002), 256–265.
8. 8 Penne, E.L., van der Weerd, N.C., van den Dorpel, M.A., et al. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 55 (2010), 77–87.
9. 9 Schiffl, H., Lang, S.M., Fischer, R., Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17 (2002), 1814–1818.
10. 10 Schiffl, H., Lang, S.M., Fischer, R., Effects of high efficiency post-dilution on-line hemodiafiltration or conventional hemodialysis on residual renal function and left ventricular hypertrophy. Int Urol Nephrol 45 (2013), 1389–1396.
11. 11 Kabanda, A., Jadoul, M., Pochet, J.M., et al. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45 (1994), 1689–1696.
12. 12 Stompór, T., Sułowicz, W., Anyszek, T., et al. Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis. Med Sci Monit 9 (2003), CR500–CR504.
13. 13 Delaney, M.P., Stevens, P.E., Al Hasani, M., et al. Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 51 (2008), 278–284.
14. 14 Marquez, I.O., Tambra, S., Luo, F.Y., et al. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6 (2011), 290–296.
15. 15 Bargman, J.M., Thorpe, K.E., Churchill, D.N., CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 12 (2001), 2158–2162.
16. 16 Diaz-Buxo, J.A., Lowrie, E.G., Lew, N.L., et al. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 33 (1999), 523–534.
17. 17 Rocco, M., Soucie, J.M., Pastan, S., McClellan, W.M., Peritoneal dialysis adequacy and risk of death. Kidney Int 58 (2000), 446–457.
18. 18 Termorshuizen, F., Dekker, F.W., van Manen, J.G., et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15 (2004), 1061–1070.
19. 19 Paniagua, R., Amato, D., Vonesh, E., et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 (2002), 1307–1320.
20. 20 Shemin, D., Bostom, A.G., Laliberty, P., Dworkin, L.D., Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38 (2001), 85–90.
21. 21 van der Wal, W.M., Noordzij, M., Dekker, F.W., et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 26 (2011), 2978–2983.
22. 22 Obi Y, Streja E, Rhee C, et al. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study [e-pub ahead of print]. Am J Kidney Dis. http://dx.doi.org/10.1053/ajkd.2016.01.008, accessed December 26, 2015.
23. 23 Hassan, K., Hassan, S., Anwar, S., et al. Predictors of left ventricular hypertrophy and their cutoffs in peritoneal dialysis patients. Int Heart J 56 (2015), 186–191.
24. 24 Voroneanu, L., Cusai, C., Hogas, S., et al. The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. Int Urol Nephrol 42 (2010), 789–797.
25. 25 Gunal, A.I., Kirciman, E., Guler, M., et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients?. Ren Fail 26 (2004), 405–409.
26. 26 Dorairajan, S., Chockalingam, A., Misra, M., Myocardial stunning in hemodialysis: what is the overall message?. Hemodial Int 14 (2010), 447–450.
27. 27 McIntyre, C.W., Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif 29 (2010), 105–110.
28. 28 Burton, J.O., Jefferies, H.J., Selby, N.M., McIntyre, C.W., Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4 (2009), 914–920.
29. 29 Burton, J.O., Jefferies, H.J., Selby, N.M., McIntyre, C.W., Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 4 (2009), 1925–1931.
30. 30 Shafi, T., Jaar, B.G., Plantinga, L.C., et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. Am J Kidney Dis 56 (2010), 348–358.
31. 31 Palomo-Piñón, S., Mora-Villalpando, C.J., Del Carmen Prado-Uribe, M., et al. Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients. Arch Med Res 45 (2014), 484–488.
32. 32 Wang, A.Y., Wang, M., Woo, J., et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15 (2004), 2186–2194.
33. 33 Bemelmans, M.H., Gouma, D.J., Buurman, W.A., Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150 (1993), 2007–2017.
34. 34 Poole, S., Bird, T.A., Selkirk, S., et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 2 (1990), 416–422.
35. 35 Termorshuizen, F., Korevaar, J.C., Dekker, F.W., et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41 (2003), 1293–1302.
36. 36 Suda, T., Hiroshige, K., Ohta, T., et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 15 (2000), 396–401.
37. 37 Vilar, E., Wellsted, D., Chandna, S.M., et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24 (2009), 2502–2510.
38. 38 Penne, E.L., van der Weerd, N.C., Grooteman, M.P., et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 6 (2011), 281–289.
39. 39 Bailie, G.R., Larkina, M., Goodkin, D.A., et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87 (2015), 162–168.
40. 40 Lowrie, E.G., Laird, N.M., Parker, T.F., Sargent, J.A., Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 305 (1981), 1176–1181.
41. 41 Eknoyan, G., Beck, G.J., Cheung, A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002), 2010–2019.
42. 42 Chertow, G.M., Levin, N.W., Beck, G.J., et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 363 (2010), 2287–2300.
43. 43 Chertow, G.M., Levin, N.W., Beck, G.J., et al. Long-term effects of frequent in-center hemodialysis [e-pub ahead of print]. J Am Soc Nephrol, 2015 Oct 14 pii: ASN.2015040426. Accessed December 28, 2015.
44. 44 Rocco, M.V., Lockridge, R.S., Beck, G.J., et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 80 (2011), 1080–1091.
45. 45 Rocco, M.V., Daugirdas, J.T., Greene, T., et al. Long-term effects of frequent nocturnal hemodialysis on mortality: the Frequent Hemodialysis Network (FHN) Nocturnal Trial. Am J Kidney Dis 66 (2015), 459–468.
46. 46 Daugirdas, J.T., Greene, T., Rocco, M.V., et al. Effect of frequent hemodialysis on residual kidney function. Kidney Intl 83 (2013), 949–958.
47. 47 Obi, Y., Eriguchi, R., Ou, S.M., et al. What is known and unknown about twice-weekly hemodialysis. Blood Purif 40 (2015), 298–305.
48. 48 Levey, A.S., Coresh, J., Balk, E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003), 137–147.
49. 49 Singhal, M.K., Bhaskaran, S., Vidgen, E., et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20 (2000), 429–438.
50. 50 Johnson, D.W., Mudge, D.W., Sturtevant, J.M., et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 23 (2003), 276–283.
51. 51 Kim, J.K., Kim, S.G., Kim, M.G., et al. Left ventricular diastolic dysfunction as a predictor of rapid decline of residual renal function in patients with peritoneal dialysis. J Am Soc Echocardiogr 25 (2012), 411–420.
52. 52 Menon, M.K., Naimark, D.M., Bargman, J.M., et al. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 16 (2001), 2207–2213.
53. 53 Shin, S.K., Noh, H., Kang, S.W., et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19 (1999), 138–142.
54. 54 Nongnuch, A., Assanatham, M., Panorchan, K., Davenport, A., Strategies for preserving residual renal function in peritoneal dialysis patients. Clin Kidney J 8 (2015), 202–211.
55. 55 Hiroshige, K., Yuu, K., Soejima, M., et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 16 (1996), 307–315.
56. 56 Hufnagel, C., Michel, C., Queffeulou, G., et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 14 (1999), 1224–1228.
57. 57 Williams, J.D., Topley, N., Craig, K.J., et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66 (2004), 408–418.
58. 58 Lee, H.Y., Choi, H.Y., Park, H.C., et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21 (2006), 2893–2899.
59. 59 Fan, S.L., Pile, T., Punzalan, S., et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 73 (2008), 200–206.
60. 60 Zhang, M., Wang, M., Li, H., et al. Association of Initial Twice-Weekly Hemodialysis Treatment with Preservation of Residual Kidney Function in ESRD patients. Am J Nephrol 40 (2014), 140–150.
61. 61 McCarthy, J.T., Jenson, B.M., Squillace, D.P., Williams, A.W., Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 29 (1997), 576–583.
62. 62 Hartmann, J., Fricke, H., Schiffl, H., Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 30 (1997), 366–373.
63. 63 Caramelo, C., Alcázar, R., Gallar, P., et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 9 (1994), 675–677.
64. 64 van Olden, R.W., van Acker, B.A., Koomen, G.C., et al. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 10 (1995), 2274–2280.
65. 65 Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48:Suppl 1 (2006), S2–S90.
66. 66 Lo, W.K., Bargman, J.M., Burkart, J., et al. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 26 (2006), 520–522.
67. 67 Daugirdas, J., Blake, P., Ing, T., Handbook of Dialysis. 2014, Lippincott Williams & Wilkins, Philadelphia, PA.
68. 68 Tattersall, J., Martin-Malo, A., Pedrini, L., et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 22:Suppl 2 (2007), ii5–ii21.
69. 69 Kalantar-Zadeh, K., Unruh, M., Zager, P.G., et al. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 64 (2014), 181–186.
70. 70 Hoek, F.J., Korevaar, J.C., Dekker, F.W., et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 22 (2007), 1633–1638.
71. 71 Huang, S.H., Filler, G., Lindsay, R.M., Residual renal function calculated from serum cystatin C measurements and knowledge of the weekly standard Kt/V urea. Perit Dial Int 32 (2012), 102–104.
72. 72 Shafi T, Michels W, Levey A, et al. Estimating residual kidney function in dialysis patients without urine collection [e-pub ahead of print]. Kidney Int. http://dx.doi.org/10.1016/j.kint.2015.10.10011, accessed February 12, 2016.
73. 73 Gerhardt, T., Pöge, U., Stoffel-Wagner, B., et al. Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant 23 (2008), 309–314.
74. 74 Vilar, E., Boltiador, C., Viljoen, A., et al. Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration. Clin J Am Soc Nephrol 9 (2014), 1240–1247.
75. 75 Vilar, E., Boltiador, C., Wong, J., et al. Plasma levels of middle molecules to estimate residual kidney function in haemodialysis without urine collection. PLoS One, 10, 2015, e0143813.
76. 76 Swan, S.K., Halstenson, C.E., Kasiske, B.L., Collins, A.J., Determination of residual renal function with iohexol clearance in hemodialysis patients. Kidney Int 49 (1996), 232–235.
77. 77 Huang, S.H., Eliasziw, M., Spence, J.D., et al. The (99m)Tc-DTPA urinary clearance method may be preferable to the plasma disappearance method for assessing glomerular filtration rate in diabetic nephropathy. Nephron Clin Pract 128 (2014), 367–372.
78. 78 Casino, F.G., Marshall, M.R., Simple and accurate quantification of dialysis in acute renal failure patients during either urea non-steady state or treatment with irregular or continuous schedules. Nephrol Dial Transplant 19 (2004), 1454–1466.
79. 79 Depner, T.A., Benefits of more frequent dialysis: lower TAC at the same Kt/V. Nephrol Dial Transplant 13:suppl 6 (1998), 20–24.
80. 80 Depner, T.A., Hemodialysis adequacy: basic essentials and practical points for the nephrologist in training. Hemodial Int 9 (2005), 241–254.
81. 81 Leypoldt, J.K., Urea standard Kt/V(urea) for assessing dialysis treatment adequacy. Hemodial Int 8 (2004), 193–197.
82. 82 Daugirdas, J.T., Depner, T.A., Greene, T., et al. Standard Kt/V(urea): a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney Int 77 (2010), 637–644.
83. 83 Wong, J., Vilar, E., Davenport, A., Farrington, K., Incremental haemodialysis. Nephrol Dial Transplant 30 (2015), 1639–1648.
84. 84 Lin, Y.F., Huang, J.W., Wu, M.S., et al. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton) 14 (2009), 59–64.
85. 85 Hanson, J.A., Hulbert-Shearon, T.E., Ojo, A.O., et al. Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol 19 (1999), 625–633.
86. 86 Cooper, B.A., Branley, P., Bulfone, L., et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363 (2010), 609–619.
87. 87 Vanholder, R., Davenport, A., Hannedouche, T., et al. Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol 23 (2012), 1291–1298.
88. 88 Janousek, R., Krajina, A., Peregrin, J.H., et al. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol 33 (2010), 61–66.
89. 89 Dittrich, E., Puttinger, H., Schillinger, M., et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients–a prospective study. Nephrol Dial Transplant 21 (2006), 1334–1339.
90. 90 Jassal, S.V., Lok, C.E., Walele, A., Bargman, J.M., Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. Am J Kidney Dis 40 (2002), 178–183.
91. 91 James, S.H., Meyers, A.M., Milne, F.J., Reinach, S.G., Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension. Nephron 71 (1995), 29–34.
92. 92 Xydakis, D., Papadogiannakis, A., Sfakianaki, M., et al. Residual renal function in hemodialysis patients: the role of angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol, 2013, 2013, 184527.
93. 93 Agarwal, R., Sinha, A.D., Pappas, M.K., et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 29 (2014), 672–681.
94. 94 Medcalf, J.F., Harris, K.P., Walls, J., Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59 (2001), 1128–1133.
95. 95 van Olden, R.W., Guchelaar, H.J., Struijk, D.G., et al. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 23 (2003), 339–347.
96. 96 Bragg-Gresham, J.L., Fissell, R.B., Mason, N.A., et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49 (2007), 426–431.
97. 97 Fishbane, S., Natke, E., Maesaka, J.K., Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis 28 (1996), 257–261.
98. 98 Anderson, J.V., Raine, A.E., Proudler, A., Bloom, S.R., Effect of haemodialysis on plasma concentrations of atrial natriuretic peptide in adult patients with chronic renal failure. J Endocrinol 110 (1986), 193–196.
99. 99 Zoccali, C., Ciccarelli, M., Mallamaci, F., et al. Effect of ultrafiltration on plasma concentrations of atrial natriuretic peptide in haemodialysis patients. Nephrol Dial Transplant 1 (1986), 188–191.
100. 100 Lauster, F., Gerzer, R., Weil, J., et al. Assessment of dry body-weight in haemodialysis patients by the biochemical marker cGMP. Nephrol Dial Transplant 5 (1990), 356–361.
101. 101 Lauster, F., Fülle, H.J., Gerzer, R., Schiffl, H., The postdialytic plasma cyclic guanosine 3':5'-monophosphate level as a measure of fluid overload in chronic hemodialysis. J Am Soc Nephrol 2 (1992), 1451–1454.
102. 102 Cheriex, E.C., Leunissen, K.M., Janssen, J.H., et al. Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. Nephrol Dial Transplant 4 (1989), 563–568.
103. 103 Katzarski, K., Charra, B., Laurent, G., et al. Multifrequency bioimpedance in assessment of dry weight in haemodialysis. Nephrol Dial Transplant 11:Suppl 2 (1996), 20–23.
104. 104 de Vries, J.P., Kouw, P.M., van der Meer, N.J., et al. Non-invasive monitoring of blood volume during hemodialysis: its relation with post-dialytic dry weight. Kidney Int 44 (1993), 851–854.
105. 105 Lysaght, M.J., Vonesh, E.F., Gotch, F., et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 37 (1991), 598–604.
106. 106 Misra, M., Vonesh, E., Van Stone, J.C., et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 59 (2001), 754–763.
107. 107 Van Biesen, W., Vanholder, R.C., Veys, N., et al. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 11 (2000), 116–125.
108. 108 Stannat, S., Bahlmann, J., Kiessling, D., et al. Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib Nephrol 46 (1985), 102–108.
109. 109 Caria, S., Cupisti, A., Sau, G., Bolasco, P., The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients. BMC Nephrol, 15, 2014, 172.
110. 110 Jiang, N., Qian, J., Sun, W., et al. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial. Nephrol Dial Transplant 24 (2009), 2551–2558.
111. 111 Shah, A.P., Kalantar-Zadeh, K., Kopple, J.D., Is there a role for ketoacid supplements in the management of CKD?. Am J Kidney Dis 65 (2015), 659–673.
112. 112 Kalantar-Zadeh, K., Ikizler, T.A., Let them eat during dialysis: an overlooked opportunity to improve outcomes in maintenance hemodialysis patients. J Ren Nutr 23 (2013), 157–163.
113. 113 Kistler, B., Benner, D., Burgess, M., et al. To eat or not to eat-international experiences with eating during hemodialysis treatment. J Ren Nutr 24 (2014), 349–352.